Back to top
more

Amedisys (AMED)

(Delayed Data from NSDQ)

$96.80 USD

96.80
523,757

-0.91 (-0.93%)

Updated Nov 7, 2024 04:00 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value B Growth C Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 20% (51 out of 251)

Industry: Medical - Outpatient and Home Healthcare

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Here is Why Growth Investors Should Buy Amedisys (AMED) Now

by Zacks Equity Research

Amedisys (AMED) could produce exceptional returns because of its solid growth attributes.

Zacks.com featured highlights include: Exantas Capital, Lamb Weston, Bristol-Myers Squibb, Amedisys and Computer Programs and Systems

by Zacks Equity Research

Zacks.com featured highlights include: Exantas Capital, Lamb Weston, Bristol-Myers Squibb, Amedisys and Computer Programs and Systems

Swayta Shah headshot

5 Stocks With Upgraded Broker Ratings Worth Betting on Now

by Swayta Shah

Brokers have more understanding of fundamentals of a company, and also about the overall economy. So, following broker advice is a wise decision.

Amedisys (AMED) Tops Earnings and Revenue Estimates in Q1

by Zacks Equity Research

At Home Health and Hospice divisions, Amedisys (AMED) witnesses solid year-over-year growth in Medicare and non-Medicare revenues.

Amedisys (AMED) Upgraded to Buy: Here's What You Should Know

by Zacks Equity Research

Amedisys (AMED) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Zacks.com featured highlights include: Raytheon, Otter, Amedysis, Tutor and DMC

by Zacks Equity Research

Zacks.com featured highlights include: Raytheon, Otter, Amedysis, Tutor and DMC

Amedisys (AMED) is an Incredible Growth Stock: 3 Reasons Why

by Zacks Equity Research

Amedisys (AMED) is well positioned to outperform the market, as it exhibits above-average growth in financials.

Buy These 5 Low Leverage Stocks to Avoid Huge Losses

by Zacks Equity Research

Companies with large debt loads are more vulnerable during economic downturns and can even go bankrupt in the worst-case scenario

Sumit Singh headshot

These 5 Stocks Boast Impressive Interest Coverage Ratio

by Sumit Singh

Interest Coverage Ratio is used to determine how effectively a company can pay the interest charges on its debt.

Amedisys (AMED) Reports Next Week: Wall Street Expects Earnings Growth

by Zacks Equity Research

Amedisys (AMED) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Edwards Lifesciences Takes Over CAS Medical Systems for $100M

by Zacks Equity Research

This CASMED acquisition is expected to strengthen Edwards Lifesciences' (EW) critical care portfolio and expand its footprint in the smart monitoring technology market.

Here's Why You Should Invest in Chemed (CHE) Stock Right Now

by Zacks Equity Research

Chemed (CHE) is expected to benefit from the launch of its VITAS Healthcare Inpatient Hospice Unit.

Medidata Launches Acorn Artificial Intelligence Company

by Zacks Equity Research

Driven by Medidata's (MDSO) standardized clinical data storehouse, and operating on its pioneering platform, Acorn AI is set to become one of the premier AI companies in the field of life sciences.

Hologic's Diagnostics Grows Strong, Escalating Costs a Woe

by Zacks Equity Research

To fortify its product portfolio, Hologic (HOLX) is working on innovations and product introductions. On this front, Cynosure's R&D pipeline stays robust.

    ResMed Launches AirFit P30i Nasal Pillows Mask in the US

    by Zacks Equity Research

    ResMed (RMD) to expand its portfolio of sleep apnea devices on the back of AirFit P30i nasal pillows mask.

    Medtronic's (MDT) Study Shows Positive Results of TDD Use (revised)

    by Zacks Equity Research

    The outcomes of the study demonstrates that patients on TDD along with CMM witnessed some major benefits compared to those on CMM alone.

    Zacks.com featured expert Kevin Matras highlights: Medifast, Foot Locker, Amedisys, Comfort Systems and CarGurus

    by Zacks Equity Research

    Zacks.com featured expert Kevin Matras highlights: Medifast, Foot Locker, Amedisys, Comfort Systems and CarGurus

    Zacks.com featured expert Kevin Matras highlights: WellCare Health Plans, Domtar, Amedysis, Fastenal and DMC Global

    by Zacks Equity Research

    Zacks.com featured expert Kevin Matras highlights: WellCare Health Plans, Domtar, Amedysis, Fastenal and DMC Global

    ResMed's Brightree Widens ReSupply Solution Usage for HME

    by Zacks Equity Research

    Resmed's (RMD) Brightree ReSupply is a scalable and automated solution that comprises live-agent inbound and outbound calls for more private interaction with patients and email reminder capabilities.

    Looking for a Growth Stock? 3 Reasons Why Amedisys (AMED) is a Solid Choice

    by Zacks Equity Research

    Amedisys (AMED) could produce exceptional returns because of its solid growth attributes.

    Sanghamitra Saha headshot

    5 Top-Ranked Stocks to Play DuPont Analysis

    by Sanghamitra Saha

    Have more faith in DuPont analysis than simple ROE calculation? Bet on these five stocks.

    Walgreens Partners With VillageMD to Offer Primary Healthcare

    by Zacks Equity Research

    This joint venture marks Walgreens' (WBA) commitment toward enabling access to affordable healthcare and creating neighborhood health destinations.

    Buy These 5 Low Leverage Stocks to Avoid the Perils of Debt

    by Zacks Equity Research

    Before investing blindly in a stock exhibiting solid growth traits, one should consider the extent of its leverage in order to avoid falling into debt traps.

    Here's Why You Should Hold on to DaVita (DVA) Stock Now

    by Zacks Equity Research

    DaVita (DVA) is gaining steadily from expansion in international markets, strong demand in dialysis services and prudent acquisitions. However, rising expenses remain a dampener.

    Medtronic's (MDT) Study Shows Positive Results of TDD Use

    by Zacks Equity Research

    The outcomes of the study, conducted by Medtronic (MDT), demonstrates that patients on TDD along with CMM witnessed some major benefits compared to those on CMM alone.